Antivirals for COVID-19: A critical review
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357 · cited 1×
“Ongoing clinical trials in China(119) report favipiravir treatment in patients was significantly correlated with a shorter viral clearance time as compared to untreated patients.(120) Its efficacy has also been assessed in a randomized clinical trial.”
BackgroundRetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · cited 15×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialLu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · cited 3×
“The process of endocytosis is regulated by AP2-associated protein kinase 1 (AAK1).(39) Therefore, the disruption of AAK1 will not only block the viral entry but also the intracellular viral assembly.”
BackgroundMethodInfluentialA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“An in vitro study reported that a combination of remdesivir and chloroquine, an anti-malarial drug, effectively inhibited SARS-CoV-2 growth in Vero E6 cells.(108) Clinical trials are ongoing to assess the efficacy of remdesivir for COVID-19 in the US,(109) Norway,(110) and France.”
BackgroundYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066 · cited 1×
“In the current pandemic, some available antivirals have been used to treat COVID-19 cases in some countries.(21,22) Since clinical trials to assess the efficacy of available antivirals for COVID-19 are still ongoing, the types”
BackgroundAn interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · cited 1×
“2% as of April 13, 2020.(8) SARS-CoV-2 belongs to the family Coronaviridae, subfamily Coronavirinae and genus Betacoronavirus, along with SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV).”
BackgroundStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030 · cited 1×
“prescribed medication which may alter the pharmacokinetics and plasma concentration of favipiravir.(116,117) This antiviral was associated A.”
Background
Cited by
A review: Mechanism of action of antiviral drugs
Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211002621 · Cited by 429
Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
Ullah, I., Khan, K. S., Tahir, M. J., Ahmed, A., & Harapan, H. (2021) · Vacunas · doi:10.1016/j.vacun.2021.01.001 · Cited by 302
Self-citationMorales-Paredes, C. A., Rodríguez-Díaz, J. M., & Boluda-Botella, N. (2022) · Science of The Total Environment · doi:10.1016/j.scitotenv.2021.152691 · Cited by 197
Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials
Selvaraj, V., Finn, A., Lal, A., Khan, M. S., Dapaah-Afriyie, K., & Carino, G. P. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101489 · Cited by 101
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Metadata
- Authors
- Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H.
- Venue
- Clinical Epidemiology and Global Health
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 9
- Pages
- 90-98
- ISSN
- 2213-3984 (ISSN-L)
- OpenAlex
- W3046074789
- Cited by
- 185
- References
- 123
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.